🟢 Telix Pharmaceuticals is trading 10.03% up today after FDA approval of Pixclara for glioma imaging

Telix Pharmaceuticals is trading 10.03% up now at $12.96 after the U.S. FDA approved Pixclara on September 14, 2026, for glioma imaging.

• Pixclara is the first FDA-approved FET-PET imaging drug for brain cancer.
• The approval establishes Telix as the sole holder of an FDA-approved radiopharmaceutical imaging agent for this indication.
• The move extends September 14’s 4.34% gain and substantially outperforms a weaker market, with healthcare sector strength providing additional support.